1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Winston Medical Supply Co., Ltd.

Winston Medical Supply Co., Ltd.

TTPEX:6817
42.00
TWD
-1.55
(-3.56%)
1.11BMarket Cap
Winston Medical Supply Co., Ltd.
TPEX:6817
(Taipei Exchange)

Recent

price

42.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
9.76
9.76
10.43
28.77
29.33
32.93
38.5
37.74
38.01
- -
Revenue per Share
-0.82
-0.74
-0.27
5.68
5.04
6.04
8.62
7.15
6.37
- -
Basic EPS, GAAP
0.96
0.17
1.2
6.18
7.73
6.43
10.61
6.99
7.48
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
3.02
4
5
6.6
7
- -
Dividend per Share
11.73
10.04
9.51
15.61
17.66
19.64
23.23
23.86
23.22
19.94
Book Value per Share
9.94
9.93
9.35
15.45
17.54
19.55
23.13
23.73
23.11
19.85
Tangible Book Value per Share
35
35
35
18
18
18
18
18
18
18
Basic Weighted Avg Shares
340
342
365
505
537
607
709
695
700
- -
Sales/Revenue/Turnover
-4.62
-8.27
-2.16
16.57
21.71
22.18
27.65
22.91
20.26
- -
Operating Margin (%)
56
39
36
36
36
36
28
30
27
- -
Depreciation Expense
-29
-26
-9
100
92
111
159
132
117
- -
Net Income, GAAP
- -
- -
- -
- -
20.98
21.31
20.15
19.85
19.73
- -
Effective Tax Rate (%)
-8.4
-7.58
-2.56
19.73
17.17
18.34
22.39
18.93
16.75
- -
Profit Margin (%)
-14
-30
-34
93
174
235
301
313
299
248
Working Capital
124
92
74
64
62
56
56
48
40
36
LT Debt
226
182
173
284
325
362
428
439
428
367
Total Equity
- -
- -
- -
- -
20.23
23.26
30.14
22.9
21.04
- -
Return on Invested Capital (%)
- -
- -
- -
- -
21.02
25.31
32.28
24.6
22.38
- -
Return on Capital (%)
- -
-13.12
-5.27
43.69
30.27
32.39
40.21
30.35
27.06
- -
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
53
47
35
LT Borrowings
38
36
34
LT Finance Leases
6
4
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
18
18
18
Market Capitalization
2,109
1,519
1,111

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
678
601
611
Cash, Cash Equivalents & STI
356
299
326
Accounts Receivable, Net
72
62
66
Inventories
151
151
154
Total Current Liabilities
425
302
363
Payables & Accruals
- -
- -
- -
ST Debt
53
47
35
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
8.84%
-2.69%
Free Cash Flow
- -
10.37%
6.9%
Net Income, GAAP
- -
5.58%
-10.87%
Sales/Revenue/Turnover
- -
6.99%
0.72%
Total Cash Common Dividend
- -
- -
6.06%

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
695
2025
- -
- -
700
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
7.15
2025
- -
- -
6.37
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
6.6
2025
- -
- -
7
2026
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Winston Medical Supply Co., Ltd. (6817.TWO) develops, manufactures, and distributes pharmaceuticals, nutrition supplements, and cosmeceutical products primarily in Taiwan. The company offers sterile ophthalmic preparations including gels, suspensions, solutions, and emulsions such as "日東" latanoprost eye drops, "必目寧" eye drops 0.2%, "必目寧複方" eye drops, "富而坦" eye drops with Aeropump® 3K Valve system, and "善瞳" atropine eye drops 0.01%; hormone preparations covering birth control and oral suspensions for cancer-related cachexia; external use preparations comprising ointments; other oral preparations in forms such as powders, troches, tablets, film-coated tablets, chewables, and capsules for colds, gastrointestinal issues, and other indications; health foods exemplified by "美健生" oral suspension approved in Thailand, Myanmar, and Malaysia; medical beauty care products; generic medicines excluding health foods; and OEM services. Founded in 1975 and headquartered at No. 117 Ren'ai Street, Yanzhou District, Tainan City, Taiwan, the company operates PIC/S GMP-certified production lines for eye drugs, oral drugs, external drugs, and a dedicated hormone facility, alongside food and cosmetics manufacturing areas, serving healthcare providers and consumers with approximately 180 employees. As a subsidiary of Medigen Biotechnology Corp. since 2014, it listed on the Taipei Exchange's Emerging Stock Board in February 2021. Recent developments include Taiwan FDA approvals in 2023 for multiple glaucoma and ocular hypertension treatments such as "必目寧眼藥水0.2%", "必目寧複方眼藥水", and "富而坦眼藥水", alongside invention patents for "善瞳眼藥水0.01%" atropine composition in July 2023 and latanoprost nanoemulsion in October 2023; in 2024, the company participated in the Republic of China Ophthalmology Society mid-year meeting in June.